Abstract
Objectives: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Methods: The Phase III REsearch Evaluating Migraine Prophylaxis Therapy 1 (PREEMPT 1) is a phase 3 study, with a 24-week, double-blind, parallel-group, placebo-controlled phase followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections every 12 weeks of onabotulinumtoxinA (155 U-195 U; n = 341) or placebo (n = 338) (two cycles). The primary endpoint was mean change from baseline in headache episode frequency at week 24. Results: No significant between-group difference for onabotulinumtoxinA versus placebo was observed for the primary endpoint, headache episodes (-5.2 vs.-5.3; p = 0.344). Large within-group decreases from baseline were observed for all efficacy variables. Significant between-group differences for onabotulinumtoxinA were observed for the secondary endpoints, headache days (p =.006) and migraine days (p = 0.002). OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few subjects discontinued due to adverse events. Conclusions: There was no between-group difference for the primary endpoint, headache episodes. However, significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 793-803 |
| Number of pages | 11 |
| Journal | Cephalalgia |
| Volume | 30 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2010 |
Fingerprint
Keywords
- botulinum toxin A
- chronic migraine
- prophylaxis
ASJC Scopus subject areas
- Clinical Neurology
- Medicine(all)
Cite this
OnabotulinumtoxinA for treatment of chronic migraine : Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. / Aurora, S. K.; Dodick, David William; Turkel, C. C.; Degryse, R. E.; Silberstein, S. D.; Lipton, R. B.; Diener, H. C.; Brin, M. F.
In: Cephalalgia, Vol. 30, No. 7, 07.2010, p. 793-803.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - OnabotulinumtoxinA for treatment of chronic migraine
T2 - Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
AU - Aurora, S. K.
AU - Dodick, David William
AU - Turkel, C. C.
AU - Degryse, R. E.
AU - Silberstein, S. D.
AU - Lipton, R. B.
AU - Diener, H. C.
AU - Brin, M. F.
PY - 2010/7
Y1 - 2010/7
N2 - Objectives: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Methods: The Phase III REsearch Evaluating Migraine Prophylaxis Therapy 1 (PREEMPT 1) is a phase 3 study, with a 24-week, double-blind, parallel-group, placebo-controlled phase followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections every 12 weeks of onabotulinumtoxinA (155 U-195 U; n = 341) or placebo (n = 338) (two cycles). The primary endpoint was mean change from baseline in headache episode frequency at week 24. Results: No significant between-group difference for onabotulinumtoxinA versus placebo was observed for the primary endpoint, headache episodes (-5.2 vs.-5.3; p = 0.344). Large within-group decreases from baseline were observed for all efficacy variables. Significant between-group differences for onabotulinumtoxinA were observed for the secondary endpoints, headache days (p =.006) and migraine days (p = 0.002). OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few subjects discontinued due to adverse events. Conclusions: There was no between-group difference for the primary endpoint, headache episodes. However, significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.
AB - Objectives: This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX®) as headache prophylaxis in adults with chronic migraine. Methods: The Phase III REsearch Evaluating Migraine Prophylaxis Therapy 1 (PREEMPT 1) is a phase 3 study, with a 24-week, double-blind, parallel-group, placebo-controlled phase followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections every 12 weeks of onabotulinumtoxinA (155 U-195 U; n = 341) or placebo (n = 338) (two cycles). The primary endpoint was mean change from baseline in headache episode frequency at week 24. Results: No significant between-group difference for onabotulinumtoxinA versus placebo was observed for the primary endpoint, headache episodes (-5.2 vs.-5.3; p = 0.344). Large within-group decreases from baseline were observed for all efficacy variables. Significant between-group differences for onabotulinumtoxinA were observed for the secondary endpoints, headache days (p =.006) and migraine days (p = 0.002). OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few subjects discontinued due to adverse events. Conclusions: There was no between-group difference for the primary endpoint, headache episodes. However, significant reductions from baseline were observed for onabotulinumtoxinA for headache and migraine days, cumulative hours of headache on headache days and frequency of moderate/severe headache days, which in turn reduced the burden of illness in adults with disabling chronic migraine.
KW - botulinum toxin A
KW - chronic migraine
KW - prophylaxis
UR - http://www.scopus.com/inward/record.url?scp=77953194100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953194100&partnerID=8YFLogxK
U2 - 10.1177/0333102410364676
DO - 10.1177/0333102410364676
M3 - Article
C2 - 20647170
AN - SCOPUS:77953194100
VL - 30
SP - 793
EP - 803
JO - Cephalalgia
JF - Cephalalgia
SN - 0333-1024
IS - 7
ER -